No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 24
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Faeth Therapeutics, Inc. (FTH) stock was $26.76 as of Oct 6, 2026, 10:00 AM EDT, down 1.25% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +182.4% · 3-year avg +23.5%/yr · 5-year avg -31.8%/yr
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways.
Biotechnology · Rockville, MD
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-0.78
Revenue Est.
N/A
Last Quarter Results
EPS
$-2.84
vs Estimate
$-4.76
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1FTH | $689.84M | $26.76 | -1.25% | +182.36% | -31.75% | N/A | N/A |
| 2HELP | $681.83M | $11.00 | -3.68% | N/A | N/A | N/A | vs FTH |
| 3ANNX | $678.87M | $4.14 | -1.35% | +31.49% | -26.29% | N/A | vs FTH |
| 4MDXG | $667.58M | $4.58 | +0.66% | -36.75% | -4.94% | -6.46% | vs FTH |
| 5ACHV | $715.02M | $6.96 | -0.64% | +121.94% | -4.33% | -39.18% | vs FTH |
| 6COLL | $720.03M | $22.20 | +1.51% | -36.67% | +2.15% | +1.39% | vs FTH |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 12 analysts
Average Price Target
$56.67
+111.8% upside
Low
$46.00
Current
$26.76
High
$70.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.87 | $-0.78 | $-0.69 | 2 |
| Quarter ending Dec 2026 | $-0.90 | $-0.77 | $-0.68 | 3 |
| Quarter ending Mar 2027 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Quarter ending Jun 2027 | $-0.76 | $-0.76 | $-0.76 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-16.73 | $-15.07 | $-13.19 | 6 |
| FY 2027 | $-4.82 | $-3.28 | $-2.51 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
